In a recently published study, researchers sought to elucidate if 2 treatments modulated immune response or not, despite the available evidence being conflicting. The method that made the difference and allowed them to reach their conclusions, is based on 16 human cytokines using multiplex immunoassays with the Quansys technology.

The innate immune system is the body’s crucial first defense against viral infections and it is dependent upon a group of pattern recognition receptors. cGMP-AMP Synthase (cGAS) responds to the presence of DNA in the cytosol by producing 2’,3’cGAMP. Cyclic GAMP in turn binds to STING leading to TBK1-mediated IRF3 activation and the production of type 1 IFN.

Understanding the STING cell signalling pathway and the role cGAMP plays in a number of important areas, such as infection, cancer, inflammation & senescence, relies on cGAMP measurement. Good news – Arbor Assays have just released a new cGAMP EIA kit, read on to learn more!

When scientists at ArborAssays invented the Direct Cyclic Nucleotide EIA immunoassay more than 20 years ago, they knew the kits would be popular. The direct nature of the format for the assays allows cAMP & cGMP in cells to be measured in one step. They went on to refine the assay, developing both colorimetric and chemiluminescent versions for cAMP and cGMP. But what makes them so popular?

During the past decade, mass spectrometry, notably LC/MS, has become a major approach to identify and quantify proteins in patient samples. It includes analysis before treatments to find the proper biomarkers for cancers diagnostics, and monitoring of the arising of the anti-drug antibodies in human plasma after therapies. Despite the fact that MS has pretty high sensitivity and specificity, research in biotherapeutics requires even more. Immunocapture, and so specific protein enrichment, offer an interesting immunoassay solution. Here, we present simple to use and efficient reagents to improve the immunocapture and thus the output of the MS technology.